1
|
Clardy SM, Uttard A, Du B, Catcott KC, Lancaster KL, Ditty E, Sadowsky J, Zurita J, Malli N, Qin L, Bradley SP, Avocetien K, Carter T, Kim D, Nazzaro M, Xu L, Pillow TH, Zacharias NT, Lewis GD, Rowntree RK, Iyengar R, Lee DH, Damelin M, Toader D, Lowinger TB. Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios. Mol Cancer Ther 2024; 23:84-91. [PMID: 37774393 DOI: 10.1158/1535-7163.mct-23-0262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 07/21/2023] [Accepted: 09/21/2023] [Indexed: 10/01/2023]
Abstract
Key defining attributes of an antibody-drug conjugate (ADC) include the choice of the targeting antibody, linker, payload, and the drug-to-antibody ratio (DAR). Historically, most ADC platforms have used the same DAR for all targets, regardless of target characteristics. However, recent studies and modeling suggest that the optimal DAR can depend on target expression level and intratumoral heterogeneity, target internalization and trafficking, and characteristics of the linker and payload. An ADC platform that enables DAR optimization could improve the success rate of clinical candidates. Here we report a systematic exploration of DAR across a wide range, by combining THIOMAB protein engineering technology with Dolasynthen, an auristatin-based platform with monomeric and trimeric variants. This approach enabled the generation of homogeneous, site-specific ADCs spanning a discrete range of DARs 2, 4, 6, 12, and 18 by conjugation of trastuzumab IgG1 THIOMAB constructs with 1, 2, or 3 engineered cysteines to monomeric or trimeric Dolasynthen. All ADCs had physicochemical properties that translated to excellent in vivo pharmacology. Following a single dose of ADCs in a HER2 xenograft model with moderate antigen expression, our data demonstrated comparable pharmacokinetics for the conjugates across all DARs and dose-dependent efficacy of all test articles. These results demonstrate that the Dolasynthen platform enables the generation of ADCs with a broad range of DAR values and with comparable physiochemical, pharmacologic, and pharmacokinetics profiles; thus, the Dolasynthen platform enables the empirical determination of the optimal DAR for a clinical candidate for a given target.
Collapse
Affiliation(s)
| | - Alex Uttard
- Mersana Therapeutics, Cambridge, Massachusetts
| | - Bingfan Du
- Mersana Therapeutics, Cambridge, Massachusetts
| | | | | | | | | | | | | | | | | | | | | | - Dokyong Kim
- Mersana Therapeutics, Cambridge, Massachusetts
| | | | - Ling Xu
- Mersana Therapeutics, Cambridge, Massachusetts
| | | | | | | | | | | | - David H Lee
- Mersana Therapeutics, Cambridge, Massachusetts
| | | | | | | |
Collapse
|
3
|
Sebastian KL, Zacharias NT, Philip B, Augusti KT. The hypolipidemic effect of onion (Allium cepa Linn) in sucrose fed rabbits. Indian J Physiol Pharmacol 1979; 23:27-30. [PMID: 437870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Long term administration of sucrose significantly increased triglyceride levels in normal rabbits. Effects of an aqueous extract of onion on the sucrose fed rabbits have been investigated. Administration of onion extract significantly reduced serum, liver and aorta triglycerides and serum and liver proteins. On the other hand liver free amino acids have been significantly increased in the onion treated group as compared to the sucrose fed control. The effects of onion have been ascribed to its sulfur containing principles which oxidize thiol compounds either present free or combined in a protein and NADPH which are necessary for lipid synthesis.
Collapse
|